Cargando…

Effect of Early and Delayed Commencement of Paricalcitol in Combination with Enalapril on the Progression of Experimental Polycystic Kidney Disease

Vitamin D secosteroids are intranuclear regulators of cellular growth and suppress the renin-angiotensin system. The aim of this study was to test the hypothesis that the vitamin D receptor agonist, paricalcitol (PC), either alone or with enalapril (E) (an angiotensin-converting enzyme inhibitor), r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sagar, Priyanka S., Saravanabavan, Sayanthooran, Munt, Alexandra, Wong, Annette T. Y., Rangan, Gopala K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8621425/ https://www.ncbi.nlm.nih.gov/pubmed/34821697 http://dx.doi.org/10.3390/jcdd8110144

Ejemplares similares

Regression of Peritubular Capillaries Coincides with Angiogenesis and Renal Cyst Growth in Experimental Polycystic Kidney Disease
por: O’Brien, Kristal, et al.
Publicado: (2020)

Kidney Cyst Lining Epithelial Cells Are Resistant to Low-Dose Cisplatin-Induced DNA Damage in a Preclinical Model of Autosomal Dominant Polycystic Kidney Disease
por: Saravanabavan, Sayanthooran, et al.
Publicado: (2022)

Effect of Reducing Ataxia-Telangiectasia Mutated (ATM) in Experimental Autosomal Dominant Polycystic Kidney Disease
por: Zhang, Jennifer Q. J., et al.
Publicado: (2021)

Role of DNA-Dependent Protein Kinase in Mediating Cyst Growth in Autosomal Dominant Polycystic Kidney Disease
por: Chandra, Ashley N., et al.
Publicado: (2021)

Long-term dietary nitrate supplementation does not reduce renal cyst growth in experimental autosomal dominant polycystic kidney disease
por: Zhang, Jennifer Q. J., et al.
Publicado: (2021)

Efficacy of beetroot juice on reducing blood pressure in hypertensive adults with autosomal dominant polycystic kidney disease (BEET-PKD): study protocol for a double-blind, randomised, placebo-controlled trial
por: Sagar, Priyanka S., et al.
Publicado: (2023)

Increased water intake reduces long-term renal and cardiovascular disease progression in experimental polycystic kidney disease
por: Sagar, Priyanka S., et al.
Publicado: (2019)

Cardiac and Renal Effects of Atrasentan in Combination with Enalapril and Paricalcitol in Uremic Rats
por: Ritter, Cynthia, et al.
Publicado: (2014)

Clinical characteristics and outcomes of hyponatraemia associated with oral water intake in adults: a systematic review
por: Rangan, Gopala K, et al.
Publicado: (2021)

Assessment of Dietary Sodium Intake Using the Scored Salt Questionnaire in Autosomal Dominant Polycystic Kidney Disease
por: Wong, Annette T. Y., et al.
Publicado: (2020)

Is serum copeptin a modifiable biomarker in autosomal dominant polycystic kidney disease?
por: Tasneem, Moomal, et al.
Publicado: (2018)

Relative Validity of a Beverage Frequency Questionnaire Used to Assess Fluid Intake in the Autosomal Dominant Polycystic Kidney Disease Population
por: Mannix, Carly, et al.
Publicado: (2018)

Pyrrolidine dithiocarbamate reduces the progression of total kidney volume and cyst enlargement in experimental polycystic kidney disease
por: Ta, Michelle H. T., et al.
Publicado: (2014)

Potential diagnostic biomarkers for chronic kidney disease of unknown etiology (CKDu) in Sri Lanka: a pilot study
por: Sayanthooran, Saravanabavan, et al.
Publicado: (2017)

Cardiovascular Manifestations and Management in ADPKD
por: Sagar, Priyanka S., et al.
Publicado: (2023)

Antiapoptotic Effect of Paricalcitol in Gentamicin-induced Kidney Injury
por: Suh, Sang Heon, et al.
Publicado: (2013)

Effects of enalapril and paricalcitol treatment on diabetic nephropathy and renal expressions of TNF-α, p53, caspase-3 and Bcl-2 in STZ-induced diabetic rats
por: Ahmed, Osama M., et al.
Publicado: (2019)

Effects of pyrrolidine dithiocarbamate on proliferation and nuclear factor-κB activity in autosomal dominant polycystic kidney disease cells
por: Ta, Michelle H. T., et al.
Publicado: (2015)

Incidence and survival of end-stage kidney disease due to polycystic kidney disease in Australia and New Zealand (1963–2014)
por: Fernando, Mangalee R., et al.
Publicado: (2017)

Hemodynamic and mitochondrial effects of enalapril in experimental sepsis
por: Pereira, AJ, et al.
Publicado: (2013)

Oral Paricalcitol for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease
por: Cheng, Steven, et al.
Publicado: (2006)

Paricalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients
por: Cruzado, Josep M., et al.
Publicado: (2017)

Etelcalcetide and Paricalcitol in Chronic Kidney Disease: When the Target Is Inflammation
por: D’Marco, Luis, et al.
Publicado: (2022)

Upregulation of Oxidative Stress Related Genes in a Chronic Kidney Disease Attributed to Specific Geographical Locations of Sri Lanka
por: Sayanthooran, Saravanabavan, et al.
Publicado: (2016)

Autosomal dominant polycystic kidney disease (ADPKD) is associated with coronary arterial dilatation in end-stage renal failure patients
por: Chiha, Joseph, et al.
Publicado: (2012)

Impaired angiogenesis in the enalapril-treated neonatal rat kidney
por: Yim, Hyung Eun, et al.
Publicado: (2016)

Preclinical Therapy with Vitamin D3 in Experimental Encephalomyelitis: Efficacy and Comparison with Paricalcitol
por: Mimura, Luiza Ayumi Nishiyama, et al.
Publicado: (2021)

Differential expression and regulation of Klotho by paricalcitol in the kidney, parathyroid and aorta of uremic rats
por: Ritter, Cynthia S., et al.
Publicado: (2015)

Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease
por: Webb, Nicholas J. A., et al.
Publicado: (2017)

Paricalcitol Attenuates Contrast-Induced Acute Kidney Injury by Regulating Mitophagy and Senescence
por: Bae, Eunjin, et al.
Publicado: (2020)

Effects of TORC1 Inhibition during the Early and Established Phases of Polycystic Kidney Disease
por: Ta, Michelle H. T., et al.
Publicado: (2016)

Paricalcitol vs. cinacalcet for secondary hyperparathyroidism in chronic kidney disease: A meta-analysis
por: Xu, Wei, et al.
Publicado: (2020)

Paricalcitol Improves Hypoxia-Induced and TGF-β1-Induced Injury in Kidney Pericytes
por: Lim, Jeong-Hoon, et al.
Publicado: (2021)

RAPID-ADPKD (Retrospective epidemiological study of Asia-Pacific patients with rapId Disease progression of Autosomal Dominant Polycystic Kidney Disease): study protocol for a multinational, retrospective cohort study
por: Ryu, Hyunjin, et al.
Publicado: (2020)

Is the combination of enalapril and losartan irrational?
por: Parmar, D.M., et al.
Publicado: (2008)

Drug management of autosomal dominant polycystic kidney disease
por: Theivendran, Thiveya, et al.
Publicado: (2022)

Comparison of the Pharmacological Effects of Paricalcitol and Doxercalciferol on the Factors Involved in Mineral Homeostasis
por: Wu-Wong, J. Ruth, et al.
Publicado: (2010)

Meta-Analysis: The Efficacy and Safety of Paricalcitol for the Treatment of Secondary Hyperparathyroidism and Proteinuria in Chronic Kidney Disease
por: Han, Tianzhao, et al.
Publicado: (2013)

Paricalcitol does not improve glucose metabolism in patients with stage 3-4 chronic kidney disease
por: de Boer, Ian H., et al.
Publicado: (2012)

Cost-effectiveness analysis of cinacalcet vs. paricalcitol in the treatment of hyperparathyroidism secondary to chronic kidney disease
por: Ponce, Daniela, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3dulj1irt1hc7tlfsq1031rsai